HOME >> MEDICINE >> NEWS
ZYVOX(R) demonstrates high success rate for patients who develop MRSA surgical site infections

New York, Dec. 15, 2004 Surgical patients treated with Pfizer's novel antibiotic ZYVOX (linezolid; injection, tablets, and for oral suspension) had a significantly higher rate of microbiologic success (documented or presumed eradication) than those treated with intravenous (IV) vancomycin for surgical site infections (SSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA), according to data published in the December issue of the American Journal of Surgery. In addition, the mean duration of IV treatment was significantly shorter (6 days) for patients who received ZYVOX than for those treated with vancomycin. Post-operative surgical site infections remain a major source of illness and number approximately 500,000 per year.

In the post-hoc analysis, patients in the MRSA subgroup treated with ZYVOX had microbiologic success rates of 87 percent compared to 48 percent for patients on vancomycin. Clinical cure rates for ZYVOX-treated patients were comparable to those treated with vancomycin for all SSIs, including those caused by MRSA. ZYVOX, available in interchangeable IV and oral formulations, is the only oral therapy approved by the U.S. Food and Drug Administration for MRSA infections.

Patients who develop SSIs are 60 percent more likely to spend time in an intensive care unit, five times more likely to be readmitted to the hospital and twice as likely to die. Hard-to-treat resistant bacteria such as MRSA are further complicating these infections. MRSA is extremely serious and can lead to prolonged hospitalization, increased morbidity, increased risk of mortality, and increased costs (driven by length of hospital stay). Data show that MRSA caused 30 percent of SSIs in 2000 compared to 24 percent in 1997.

"As the prevalence of surgical site infections caused by MRSA increases, identifying MRSA early and having alternatives to vancomycin becomes extremely important since any patient undergoing surgery is at risk," said
'"/>

Contact: Jeanne Traflet
Jeanne.Traflet@Pfizer.com
212-733-0127
Edelman Public Relations
15-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. New study in Nature demonstrates protection against cell death during heart attack
2. New study demonstrates co-administration
3. New data demonstrates that Benicar(R) and Benicar HCT (TM) achieve JNC 7 blood pressure goals
4. New study demonstrates significant and sustained improvements in BPH symptoms with AVODART ™
5. New Canadian study demonstrates clear survival benefit of treatment in trials and at large centres
6. New study demonstrates key benefits of RISPERDAL(R) CONSTA(R) in young adults with schizophrenia
7. UF smart home demonstrates concept of automated elderly help and care
8. Study demonstrates improved survival in women with metastatic breast cancer
9. CHARM* Programme demonstrates clear benefits of Atacand in the treatment of heart failure
10. Residential addiction treatment demonstrates economic benefits
11. New P.E. study demonstrates vigorous exercise can lower adolescents body fat, blood pressure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... NEWPORT BEACH, Calif. (PRWEB) , ... July 17, 2020 , ... A June 2 ... reality show, Botched, to seek help for her mishandled breast augmentations. The article says that ... surgeon, as she had assumed. The woman then found a surgeon to revise her procedure, ...
(Date:7/18/2020)... ... July 17, 2020 , ... Nader Sanai, M.D., director of the Ivy Brain ... the second annual Glioblastoma Awareness Day (#GBMDay) on July 22, 2020 to raise national ... of glioblastoma , the most common and aggressive form of brain cancer. It ...
(Date:7/10/2020)... ... July 10, 2020 , ... Circularity announced a ... Healthcare’s mission to provide real and affordable healthcare solutions , will create ... pandemics by ending the commercial trade in wild animals, expanding wild habitats, and ...
(Date:7/10/2020)... ... July 09, 2020 , ... CellTrak, the ... health announces that Ohio Department of Medicaid has awarded CellTrak Phase 2 EVV ... in Ohio already rely on CellTrak for EVV – both as a point-of-care ...
(Date:7/10/2020)... MANHATTAN BEACH, Calif. (PRWEB) , ... July 10, 2020 , ... ... training , today announced a new training course for managers on the Family and ... expands the FMLA with paid sick and family leave provisions related to COVID-19. ...
Breaking Medicine News(10 mins):
(Date:7/18/2020)... ... July 17, 2020 , ... A Perspective ... to illustrate how implicit bias among psychiatrists and other clinicians can affect patient-clinician ... minority people. The Perspective was authored by researchers at The Fenway Institute and ...
(Date:7/10/2020)... ... July 10, 2020 , ... Precision ... advanced manufacturing solutions provider today announced that their CANSWAB™ nasopharyngeal swabs are the ... has engineered a new 3D-printed swab design and has trademarked the name CANSWAB™ ...
(Date:7/10/2020)... ... July 10, 2020 , ... ... 25 years of experience and more than 12 million guests, unveiled its new ... it promotes care and attention in all facets of the operation, safety, and ...
Breaking Medicine Technology:
Cached News: